HRP20130527T1 - Disubstituted phthalazine hedgehog pathway antagonists - Google Patents

Disubstituted phthalazine hedgehog pathway antagonists

Info

Publication number
HRP20130527T1
HRP20130527T1 HRP20130527AT HRP20130527T HRP20130527T1 HR P20130527 T1 HRP20130527 T1 HR P20130527T1 HR P20130527A T HRP20130527A T HR P20130527AT HR P20130527 T HRP20130527 T HR P20130527T HR P20130527 T1 HRP20130527 T1 HR P20130527T1
Authority
HR
Croatia
Prior art keywords
hedgehog pathway
pathway antagonists
disubstituted phthalazine
phthalazine hedgehog
disubstituted
Prior art date
Application number
HRP20130527AT
Other languages
English (en)
Croatian (hr)
Inventor
Jolie Anne Bastian
Philip Arthur Hipskind
Daniel Jon Sall
Takako Wilson
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41566219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20130527(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20130527T1 publication Critical patent/HRP20130527T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HRP20130527AT 2008-11-03 2009-10-22 Disubstituted phthalazine hedgehog pathway antagonists HRP20130527T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11070308P 2008-11-03 2008-11-03
PCT/US2009/061573 WO2010062507A1 (en) 2008-11-03 2009-10-22 Disubstituted phthalazine hedgehog pathway antagonists

Publications (1)

Publication Number Publication Date
HRP20130527T1 true HRP20130527T1 (en) 2013-07-31

Family

ID=41566219

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130527AT HRP20130527T1 (en) 2008-11-03 2009-10-22 Disubstituted phthalazine hedgehog pathway antagonists

Country Status (29)

Country Link
US (1) US8404687B2 (cg-RX-API-DMAC7.html)
EP (1) EP2364185B1 (cg-RX-API-DMAC7.html)
JP (1) JP2012507535A (cg-RX-API-DMAC7.html)
KR (1) KR101335746B1 (cg-RX-API-DMAC7.html)
CN (1) CN102202737B (cg-RX-API-DMAC7.html)
AU (1) AU2009320251C1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0921437A2 (cg-RX-API-DMAC7.html)
CA (1) CA2742539C (cg-RX-API-DMAC7.html)
CL (1) CL2011000979A1 (cg-RX-API-DMAC7.html)
CO (1) CO6382123A2 (cg-RX-API-DMAC7.html)
CR (1) CR20110202A (cg-RX-API-DMAC7.html)
CY (1) CY1114023T1 (cg-RX-API-DMAC7.html)
DK (1) DK2364185T3 (cg-RX-API-DMAC7.html)
EA (1) EA018931B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP11011021A (cg-RX-API-DMAC7.html)
ES (1) ES2418479T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20130527T1 (cg-RX-API-DMAC7.html)
IL (1) IL211841A0 (cg-RX-API-DMAC7.html)
MA (1) MA32726B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011004683A (cg-RX-API-DMAC7.html)
NZ (1) NZ591945A (cg-RX-API-DMAC7.html)
PE (1) PE20110433A1 (cg-RX-API-DMAC7.html)
PL (1) PL2364185T3 (cg-RX-API-DMAC7.html)
PT (1) PT2364185E (cg-RX-API-DMAC7.html)
SI (1) SI2364185T1 (cg-RX-API-DMAC7.html)
TN (1) TN2011000166A1 (cg-RX-API-DMAC7.html)
UA (1) UA102115C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010062507A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201102448B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2137162T3 (en) * 2007-03-15 2018-11-26 Novartis Ag Organic compounds and their applications
CN102066353B (zh) 2008-04-29 2013-12-11 伊莱利利公司 二取代的酞嗪Hedgehog通路拮抗剂
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
BRPI0921782A2 (pt) 2008-11-17 2019-09-24 Lilly Co Eli antagonistas da via hedgehog de piridazina tetrassubstituída
MX2011005176A (es) 2008-11-17 2011-05-30 Lilly Co Eli Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas.
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
WO2015073691A1 (en) 2013-11-14 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of bmp signaling
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
CN116349204A (zh) 2020-10-13 2023-06-27 奋进生物医药公司 治疗纤维化的方法
CR20250091A (es) * 2022-09-23 2025-04-10 Merck Sharp & Dohme Llc Derivados de ftalazina útiles como inhibidores de la proteína receptora 3 similar a nod.
WO2025188802A1 (en) 2024-03-05 2025-09-12 Endeavor Biomedicines, Inc. Methods of improving lung function

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
ES2162235T3 (es) 1996-01-15 2001-12-16 Janssen Pharmaceutica Nv Piridazinaminas inhibidoras de la angiogenesis.
KR100622323B1 (ko) * 1996-10-01 2006-11-30 교와 핫꼬 고교 가부시끼가이샤 질소-함유헤테로고리화합물
US6432970B2 (en) 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
AU768130B2 (en) 1998-04-09 2003-12-04 Johns Hopkins University School Of Medicine, The Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
AU780358B2 (en) 1999-06-08 2005-03-17 Lorantis Limited Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
CA2483311A1 (en) 2002-04-22 2003-10-30 Philip A. Beachy Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
WO2005080378A1 (ja) 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation 縮合ピリダジン誘導体
CA2564996A1 (en) 2004-05-08 2006-01-12 Taeyoung Yoon 3-aryl-5,6-disubstituted pyridazines
KR20180122750A (ko) * 2004-09-02 2018-11-13 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
DK2137162T3 (en) * 2007-03-15 2018-11-26 Novartis Ag Organic compounds and their applications
US8153633B2 (en) 2007-06-25 2012-04-10 Amgen Inc. Phthalazine compounds, compositions and methods of use
WO2009035568A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
CN102066353B (zh) 2008-04-29 2013-12-11 伊莱利利公司 二取代的酞嗪Hedgehog通路拮抗剂
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
BRPI0921782A2 (pt) 2008-11-17 2019-09-24 Lilly Co Eli antagonistas da via hedgehog de piridazina tetrassubstituída
MX2011005176A (es) 2008-11-17 2011-05-30 Lilly Co Eli Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas.
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Also Published As

Publication number Publication date
CR20110202A (es) 2011-06-09
AU2009320251A1 (en) 2010-06-03
CA2742539C (en) 2014-05-06
NZ591945A (en) 2012-10-26
HK1159010A1 (en) 2012-07-27
AU2009320251C1 (en) 2013-08-15
SI2364185T1 (sl) 2013-07-31
BRPI0921437A2 (pt) 2018-10-30
JP2012507535A (ja) 2012-03-29
ES2418479T3 (es) 2013-08-14
CA2742539A1 (en) 2010-06-03
CN102202737B (zh) 2014-03-26
EP2364185B1 (en) 2013-05-22
TN2011000166A1 (en) 2012-12-17
DK2364185T3 (da) 2013-06-03
EP2364185A1 (en) 2011-09-14
UA102115C2 (ru) 2013-06-10
CY1114023T1 (el) 2016-07-27
CN102202737A (zh) 2011-09-28
CO6382123A2 (es) 2012-02-15
IL211841A0 (en) 2011-06-30
EA201170640A1 (ru) 2011-12-30
PL2364185T3 (pl) 2013-10-31
MX2011004683A (es) 2011-06-20
WO2010062507A1 (en) 2010-06-03
US20110190304A1 (en) 2011-08-04
CL2011000979A1 (es) 2011-10-07
PT2364185E (pt) 2013-07-24
KR101335746B1 (ko) 2013-12-12
ZA201102448B (en) 2012-09-26
US8404687B2 (en) 2013-03-26
KR20110066212A (ko) 2011-06-16
PE20110433A1 (es) 2011-07-09
ECSP11011021A (es) 2011-06-30
EA018931B1 (ru) 2013-11-29
MA32726B1 (fr) 2011-10-02
AU2009320251B2 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
IL208211A0 (en) Disubstituted phthalazine hedgehog pathway antagonists
ZA201108587B (en) Disubstituted phthalazine hedgehog pathway antagonists
ZA201102448B (en) Disubstituted phthalazine hedgehog pathway antagonists
IL237391A0 (en) Pharmaceutical combination
IL229059A (en) 9pcsk antagonists
IL207378A0 (en) Pharmaceutical solid state forms
DK2301489T3 (en) Tredimensionelt ortopædisk udstyr til rygsøjlen
GB201106730D0 (en) Analyzing event
AU322206S (en) Monitor
HU0800591D0 (en) Stable pharmaceutical combination
IL208953A0 (en) Pharmaceutical combination
HU0800414D0 (en) Pharmaceutical combination
HK1153467A (en) Disubstituted phthalazine hedgehog pathway antagonists
GB0818712D0 (en) Therapeutic substances
GB0810952D0 (en) Therapeutic substances
GB0812816D0 (en) Therapeutic substances
GB0804377D0 (en) Therapeutic substances
GB0802576D0 (en) Dosage form
AU2008298V (en) Proquest D3 Dianella caerulea
GB0807453D0 (en) General problem solver
HU3495U (en) Construction set
GB0819442D0 (en) Monitor
GB0805729D0 (en) K9 easybath
GB0704123D0 (en) Dosage form